Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

BACKGROUND: Thrombotic events are reduced with cangrelor, an intravenous P2Y(12) inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Su...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavender, Matthew A., Harrington, Robert A., Stone, Gregg W., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Lopes, Renato D., Leonardi, Sergio, Deliargyris, Efthymios N., Prats, Jayne, Mahaffey, Kenneth W., White, Harvey D., Bhatt, Deepak L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765214/
https://www.ncbi.nlm.nih.gov/pubmed/34915723
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.010390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765214/
https://www.ncbi.nlm.nih.gov/pubmed/34915723
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.120.010390

Ejemplares similares